Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]Global Strategy for the Diagnosis, Management, and Prevention of COPD2018 Available from: http://goldcopd.org/Accessed December 9, 2017
   Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFSethiSEffect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trialAm J Respir Crit Care Med2016194555956727585384
   PubMed Web of Science ®Google Scholar
• VosWHajianBDe BackerJFunctional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMAInt J Chron Obstruct Pulmon Dis20161126327126917956
   PubMed Web of Science ®Google Scholar
• KardosPWorsleySSinghDRoman-RodriguezMNewbyDEMullerovaHRandomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled broncho-dilator therapy in COPDInt J Chron Obstruct Pulmon Dis2016112885289527932872
   PubMedGoogle Scholar
• HerlandKAkselsenJPSkjonsbergOHBjermerLHow representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?Respir Med2005991111915672843
   PubMed Web of Science ®Google Scholar
• ChongJLeungBPoolePPhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00230924190161
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics (Europe): Daxas^® 500 microgram film-coated tablets [webpage on the Internet]AstraZeneca Pharmaceuticals2016 Available from: http://www.ema.europa.eu/ema/Accessed December 9, 2017
   Google Scholar
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJ Int Bioethique200415112412915835069
   PubMedGoogle Scholar
• EpsteinMGuidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiol Drug Saf200514858959515918159
   PubMed Web of Science ®Google Scholar
• van der MolenTWillemseBWSchokkerSten HackenNHPostmaDSJuniperEFDevelopment, validity and responsiveness of the Clinical COPD QuestionnaireHealth Qual Life Outcomes200311312773199
   PubMedGoogle Scholar
• JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
   PubMed Web of Science ®Google Scholar
• KocksJWTuinengaMGUilSMvan den BergJWStahlEvan der MolenTHealth status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaireRespir Res200676216603063
   PubMed Web of Science ®Google Scholar
• KonSSCCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
   PubMed Web of Science ®Google Scholar
• TzanakisNGinisAPolitisGQuality of life and symptoms improvement after 6 months treatment with roflumilast 500 μg daily in a large Greek COPD cohortEur Respir J201342Suppl 57P2385
   Google Scholar
• BuhlRCrieeCPKardosPA year in the life of German patients with COPD: the DACCORD observational studyInt J Chron Obstruct Pulmon Dis2016111639164627499620
   PubMed Web of Science ®Google Scholar
• KardosPVogelmeierCWorthHA two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational studyRespir Med2017124576428284322
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellDWitteSBredenbrokerDBethkeTDRoflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet2005366948556357116099292
   PubMed Web of Science ®Google Scholar
• De BackerWVosWVan HolsbekeCThe effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patientsEur Respir J20144452752924791831
   PubMed Web of Science ®Google Scholar
• HanMKKimMGMardonRSpirometry utilization for COPD: how do we measure up?Chest2007132240340917550936
   PubMed Web of Science ®Google Scholar
• MiravitllesMde la RozaCNaberanKLambanMGobarttEMartinAUse of spirometry and patterns of prescribing in COPD in primary careRespir Med200710181753176017448651
   PubMed Web of Science ®Google Scholar
• ArneMLisspersKStällbergBHow often is diagnosis of COPD confirmed with spirometry?Respir Med2010104455019931443
   PubMed Web of Science ®Google Scholar
• KimKHKangHSKimJSYoonHKKimSKRheeCKRisk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2017123449345629270006
   PubMed Web of Science ®Google Scholar
• LahuGHunnemeyerADilettiEPopulation pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phospho-diesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event modelClin Pharmacokinet201049958960620690782
   PubMed Web of Science ®Google Scholar
• LahuGFaciusAApplication of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerabilityInt J Clin Pharmacol Ther2013511183283624152603
   PubMed Web of Science ®Google Scholar
• HwangHShinJYParkKREffect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary diseaseTuberc Respir Dis (Seoul)201578432132526508918
   PubMedGoogle Scholar
• RabeKFRennardSAlagappanVKTUse of a 4-week up-titration regimen of roflumilast in patients with severe COPDInt J Chron Obstruct Pulmon Dis20181381382229563781
   PubMed Web of Science ®Google Scholar
• WorthHBuhlRCrieeCPKardosPMailanderCVogelmeierCThe ‘real-life’ COPD patient in Germany: the DACCORD studyRespir Med2016111647126775251
   PubMed Web of Science ®Google Scholar